Skip to content
Triangle logo TriangleGet started
← Study library

NCT02650986 · REGISTRY CONDITION SEARCH

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
ACTIVE NOT RECRUITING
Registry last update
2026-07-08

This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens 1 (NY-ESO-1) gene that have spread to other places in the body (advanced). A T cell is a type of immune cell that can recognize and kill abnormal cells of the body. Placing a modified gene for NY-ESO-1 into the patients' T cells in the laboratory and then giving them back to the patient may help the body build an immune response to kill tumor cells that express NY-ESO-1. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving gene-modified T cells with or without decitabine works better in treating patients with malignancies expressing NY-ESO-1.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Dose Limiting Toxicities

→

outcome · POSTED

Number of Participants With Feasibility Concerns in Manufacturing of NY-ESO-1/ dnTGFbetaRII Engineered Cells

→

outcome · NOT POSTED

Expression of the NY-ESO-1 T Cell Receptor (TCR) Transgenic Protein in Peripheral Blood Mononuclear Cells (PBMC)

→

outcome · NOT POSTED

Replication Competent Retrovirus (RCR)

→

outcome · NOT POSTED

Tumor Response (Complete and Partial Response)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients with solid tumors as described below: * Inoperable or metastatic (advanced) melanoma: * Has received, is intolerant, or refused a CTLA-4 inhibitor (ipilimumab) or a PD-1 inhibitor (nivolumab or pembrolizumab) as monotherapy and/or a combination of ipilimumab and nivolumab * Has received or is intolerant of a BRAF inhibitor or the combination of BRAF and MEK inhibitors for BRAFv600 mutant melanoma and a PD-1 inhibitor as monotherapy or in combination * Inoperable or metastatic (advanced) ovarian, primary peritoneal or fallopian tube carcinoma: * Has received platinum containing chemotherapy and has platinum refractory or resistant disease that has progressed on second line therapy * If platinum sensitive disease, should have received \>= 2 lines of chemotherapy * May have received PARP inhibitors, bevacizumab or other targeted VEGF inhibitor therapy * Inoperable or metastatic (advanced) synovial sarcoma: * Should have received and progressed on \>= two lines of systemic therapy * Subjects with other histologies: * Must have previously received two lines of systemic standard care (or effective salvage chemotherapy regimens) for metastatic disease, if known to be effective for that disease, and have been deemed either non-responders (progressive disease) or have recurred * For cohorts 1, 2 and 3 only: Patient's tumor must be positive by histological or molecular assay for NY-ESO-1, according to the screening algorithm; historical results may be used * For cohort 4, NY-ESO-1 results will be noted but NY-ESO-1 positivity is not required for eligibility * Human leukocyte antigen (HLA)-A\*0201 (HLA-A2.1) positivity by molecular subtyping (blood test or buccal swab, historical documentation acceptable) * Age \>= 18 years old, (Cohort 4: Age \>= 12 years old) * Life expectancy greater than 3 months assessed by a study physician * Have been informed of other treatment options * A minimum of one measurable lesion defined as: * Meeting the criteria for measurable disease according to irRECIST criteria * For patients with skin metastases, lesions selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s) * No restriction based on prior treatments but at least 4 weeks from prior immunotherapy, or prior investigational agents. Note: Patients who have suffered \>grade 2 irAEs during previous checkpoint inhibitor therapy should be excluded. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Must have adequate venous access for apheresis * Women of childbearing potential and men must agree to use effective methods of birth control for the duration of the study and 6 months after; methods for acceptable birth control include: condoms, diaphragm or cervical cap with spermicide, intrauterine device, and hormonal contraception; it is recommended that a combination of two methods be used * Leukocytes: \>= 3,000/mcl * Absolute neutrophil count: \>= 1,000/mcl * Platelets: \>= 100,000/mcl * Total bilirubin: =\< 1.5 upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]): =\< 2.5 x institutional upper limit of normal * Creatinine: =\< 2 X ULN; if creatinine \> 2 X ULN, creatinine clearance must be \> 60 ml/min * Must be willing and able to accept the leukapheresis procedure * At screening, must have tissue available for NY-ESO-1 testing (if not previously performed) or be willing and able to undergo a fresh tissue biopsy * Patient must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure * Participant must agree to and arrange for a caregiver (age \>= 18 years old) available 24 hours a day/ 7 days a week and arrange for lodging within 45 minutes drive to Roswell Park and transportation for a period of time after discharge from the hospital; the exact amount of time will depend on the individual status as determined by the treating physician * ELIGIBILITY CRITERIA FOR A SECOND TRANSGENIC T CELL INFUSION Subjects in whom disease control was observed after the T cell infusion may be eligible for a second transgenic T cell infusion if the subject meets the following criteria: * Patient attained confirmed disease control (either complete remission \[CR\], partial remission \[PR\] or stable disease \[SD\]) after the first transgenic T cell infusion * Patient still meets the eligibility criteria above * A second T cell infusion is discussed and the patient agrees to receive it * Either cryopreserved extra cells from the first T cell product is available or cryopreserved autologous peripheral blood mononuclear cell (PBMC) is available for the manufacture of a second transgenic T cell product Exclusion Criteria: * Previously known hypersensitivity to any of the agents used in this study * Currently receiving any other investigational agents. Note: Patients who have suffered \>grade 2 irAEs during previous checkpoint inhibitor therapy should be excluded. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; electrocardiogram (EKG) will be done at screening; cardiac stress test will be done as clinically indicated, the specific test to be chosen at the discretion of the treating physician. * History of severe autoimmune disease requiring steroids or other immunosuppressive treatments * History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea or bleeding, which in the investigator's opinion would place the patient at an increased risk for adverse effect or current acute colitis of any origin; treated cases with no active disease are eligible * Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 4 weeks prior to enrollment (inhaled or topical steroids at standard doses or isolated use of steroids as premedication for medical procedures to minimize allergic reaction \[e.g. computed tomography (CT) scan dye\] are allowed) * Known active infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C or cytomegalovirus (CMV) * Known cases of clinically active brain metastases (brain magnetic resonance imaging \[MRI\] as clinically indicated); prior evidence of brain metastasis successfully treated with surgery or radiation therapy will not be exclusion for participation as long as they are deemed under control at the time of study enrollment * Dementia or significantly altered mental status that would prohibit the understanding or rendering of compliance with the requirements of this protocol even with caregiver support * Pregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and 6 months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 48 hours from starting the conditioning chemotherapy * Lack of availability of a patient for immunological and clinical follow-up assessment
healthy Volunteers
false
minimum Age
12 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
    intervention Names
    1. Drug: Cyclophosphamide
    2. Other: Laboratory Biomarker Analysis
    3. Procedure: Leukapheresis
    4. Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
    label
    Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)
    type
    EXPERIMENTAL
  2. description
    Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
    intervention Names
    1. Drug: Cyclophosphamide
    2. Drug: Decitabine
    3. Other: Laboratory Biomarker Analysis
    4. Procedure: Leukapheresis
    5. Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
    label
    Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)
    2. Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)
    description
    Given IV
    name
    Cyclophosphamide
    other Names
    1. (-)-Cyclophosphamide
    2. 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
    3. Carloxan
    4. Ciclofosfamida
    5. Ciclofosfamide
    6. Cicloxal
    7. Clafen
    8. Claphene
    9. CP monohydrate
    10. CTX
    11. CYCLO-cell
    12. Cycloblastin
    type
    DRUG
  2. arm Group Labels
    1. Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)
    description
    Given IV
    name
    Decitabine
    other Names
    1. 5-Aza-2''-deoxycytidine
    2. Dacogen
    3. Decitabine for Injection
    4. Deoxyazacytidine
    5. Dezocitidine
    type
    DRUG
  3. arm Group Labels
    1. Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)
    2. Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  4. arm Group Labels
    1. Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)
    2. Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)
    description
    Undergo leukapheresis
    name
    Leukapheresis
    other Names
    1. Leukocytopheresis
    2. Therapeutic Leukopheresis
    type
    PROCEDURE
  5. arm Group Labels
    1. Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)
    2. Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)
    description
    Given IV
    name
    TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
    other Names
    1. TGFbDNRII-transduced Autologous TILs
    type
    BIOLOGICAL
Study design
allocation
NON_RANDOMIZED
intervention Model
SEQUENTIAL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
15
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Will be assessed using Common Toxicity Criteria. Patients will be monitored by medical histories, physical examinations, ophthalmologic exams, and blood studies to detect potential toxicities from the treatment. the number of patients experiencing a DLT are reported.
    measure
    Number of Participants With Dose Limiting Toxicities
    time Frame
    Up to 30 days
  2. description
    Unfeasibility will be defined as 3 or more preparations not meeting the lot release criteria in each cohort. Sufficient numbers of circulating, lot released confirmed T cells will be measured prior to administration. The count of patients not meeting the preparation criteria are reported.
    measure
    Number of Participants With Feasibility Concerns in Manufacturing of NY-ESO-1/ dnTGFbetaRII Engineered Cells
    time Frame
    1 month
secondary Outcomes
  1. description
    TCR and vector presence will be quantitated in PBMC samples, obtained before adoptive transfer and at weeks 1, 2, 4, 8, and 12 after transgenic cell adoptive transfer. Thereafter, sampling will be every 3 months during the first year, and then every 6 to 12 months per schedule of procedures and observations.
    measure
    Expression of the NY-ESO-1 T Cell Receptor (TCR) Transgenic Protein in Peripheral Blood Mononuclear Cells (PBMC)
    time Frame
    Up to 15 years
  2. description
    Will be assessed in blood by polymerase chain reaction (PCR).
    measure
    Replication Competent Retrovirus (RCR)
    time Frame
    Up to 1 year
  3. description
    Will be determined by immune-related Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Response assessment will be performed by comparing standard computed tomography imaging scans and photographs of target lesions from baseline.
    measure
    Tumor Response (Complete and Partial Response)
    time Frame
    Up to 90 days after TCR transgenic PBMC adoptive transfer
Full study description
brief Summary
This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens 1 (NY-ESO-1) gene that have spread to other places in the body (advanced). A T cell is a type of immune cell that can recognize and kill abnormal cells of the body. Placing a modified gene for NY-ESO-1 into the patients' T cells in the laboratory and then giving them back to the patient may help the body build an immune response to kill tumor cells that express NY-ESO-1. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving gene-modified T cells with or without decitabine works better in treating patients with malignancies expressing NY-ESO-1.
detailed Description
PRIMARY OBJECTIVE: I. To evaluate the safety and feasibility of adoptive transfer of TGFbDNRII-transduced autologous tumor infiltrating lymphocytes (autologous NY-ESO-1 TCR/dnTGFbetaRII transgenic T cells). SECONDARY OBJECTIVES: I. NY-ESO-1 TCR/ dnTGFbetaRII transgenic T cell persistence by analyzing serial peripheral blood samples for the presence of T cells with the NY-ESO-1 TCR by tetramer analysis. II. To study T cell differentiation that correlates with higher anti-tumor responses. III. To test the hypothesis that NY-ESO-1 TCR/dnTGFbetaRII will constitute in cells more efficient in inducing tumor regression. IV. Determine objective tumor responses by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) 1.1. EXPLORATORY OBJECTIVE: I. To evaluate the role of microbiota on the therapeutic efficacy of the proposed therapy. OUTLINE: This is a phase I, dose-escalation study of NY-ESO-1 TCR/TGFbDNRII-transduced TILs followed by a phase IIa study. Participants are assigned 1 to 2 cohorts. COHORT I: Patients undergo leukapheresis on day -6, and receive cyclophosphamide intravenously (IV) over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed. COHORT II: Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed. After completion of study treatment, patients are followed up at weeks 1-4, 6, 8, and 12, at 6 and 9 months, every 6 months for 5 years, and then yearly for 10 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-6204bf81b65665fd6a62
      requested nct id
      NCT02650986
      primary nct id
      NCT02650986
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
      payload sha256
      b5364f412c104998350b7f5b51d264acad509902d62ad5e62d4a63826fb80817
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-6204bf81b65665fd6a62
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02650986
      occurrences
      1. context exact
        NCT02650986
        end
        11
        exact text
        NCT02650986
        start
        0
      offset unit
      unicode_code_points
      query cond
      Ovarian Germ Cell Tumors
      query disease state id
      ds-ovarian-germ-cell-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-ovarian-germ-cell-tumors-000.json
      source file sha256
      359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
      source json pointer
      /studies/9/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      d40e08b75619b1d1d148bddb9b5edd0743312f1df5381838c3f63df10797ff73

    Preserved source evidence · Not medical advice